100% Virtual Meeting Saturday, April 17th | 09h30 – 11h30
Important security information:
Galafold is indicated for long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency) and who have an amenable mutation1.
Treatment with GALAFOLD must be initiated and supervised by specialist physicians with experience in the diagnosis and treatment of Fabry disease.
This medicine is subject to additional monitoring, which will speed up the detection of new information about your safety.
Healthcare professionals are invited to report suspected adverse reactions.